DOW JONES26,957.59-123.77 -0.46%
S&P 5003,116.39-11.82 -0.38%
NASDAQ8,980.78+15.16 0.17%

Morgan Stanley Maintains Underweight on Biogen, Raises Price Target to $270

Morgan Stanley maintains Biogen (NASDAQ:BIIB) with a Underweight and raises the price target from $262 to $270.

Benzinga · 01/17/2020 13:20

Morgan Stanley maintains Biogen (NASDAQ:BIIB) with a Underweight and raises the price target from $262 to $270.